Eli Lilly invests $3bn in injectable drug manufacturing facility
Goal is to boost production of injectable drugs
Drug delivery & innovation
Brixton Biosciences: Drug-free pain relief for knee osteoarthritis
Neural Ice: Is this long-lasting pain therapy revolutionizing treatment?
Overcoming nonspecific binding challenges in pharmacokinetic assays
Pharmacokinetic (PK) tests form an integral part of the drug development process, helping to ensure the safety and efficacy of new drugs.
Insights from Tjoapack’s CEO: 35 years of pharma packaging:
Celebrating 35 years of innovation, Tjoapack has evolved into a leading force in pharmaceutical packaging.
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Starget Pharma’s AI-Driven Cancer Therapy Gains $5.1 Million Backing
Innovative radiotherapy offers a precision treatment alternative.
FDA grants accelerated approval to Novartis’ Scemblix as a first-line leukemia therapy
Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia.
Abzena’s advanced drug development showcased at CPHI Milan
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology.
Axonis raises $115 million to overcome drug resistance in epilepsy
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
Competitors race to launch GLP-1 drugs amid soaring weight loss demand
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
GSK beefs up US manufacturing site with $800 million investment
The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, to double its size and capacity.
CRO NovAliX teams with Bruker to advance drug development
In a move set to transform drug discovery, CRO NovAliX has partnered with Bruker, a leader in scientific instruments, through a strategic investment aimed at enhancing drug development success rates.
Seaport Therapeutics closes $225 million Series B to develop neuropsychiatric drugs
The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major depressive disorder and generalized anxiety disorder.
How a CDMO is staying on top of API and drug product manufacturing trends
As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the evolving landscape.
Women in Science: Sharmeen Roy - 'pharmacy is the perfect blend of all my favourite subjects'
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application.
Antag Therapeutics gets FDA clearance to start clinical trials with new obesity drug
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.
Drug discovery and bringing new medicine to market - the future of AI in pharma
Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a value of $22.6 billion dollars by next year (2025).
Innovent and Ask Pharm join forces to commercialize third-generation lung cancer therapy
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
Ardena debuts new nanomedicines facility at CPHI 2024
At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch of a state-of-the-art nanomedicines GMP facility in Oss, Netherlands.
Symbiosis expands sterile manufacturing with new facility and innovations
As CPHI Milan 2024 approaches, Symbiosis Pharmaceutical Services is gearing up to showcase major expansions and innovations in sterile biopharmaceutical manufacturing.
Quotient Sciences expands with mRNA Focus at CPHI 2024
During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA regulations.
CPHI 2024
CBD-based formulations from dsm-firmenich at CPHI 2024
At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.
SGD Pharma to showcase new glass packaging solutions at CPHI 2024
The company will introduce its innovative siliconized moulded glass vials, positioning itself as the only global supplier offering this technology to pharmaceutical standards.
Insilico Medicine claims phase 2 win for AI-designed drug
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.
Innovative approaches to opioid use disorder treatment
As local and state governments in the US begin to receive and distribute their opioid settlement funds, Sonara Health has developed a comprehensive report analyzing how over $50 billion in national funds can be effectively allocated to address the opioid...
Metagenomics revolution: Empress Therapeutics on drug discovery breakthroughs
Dr Dawn Thompson has over 20 years of experience in building technology platforms that leverage genomics at scale to produce novel products.
ARS Pharmaceuticals’ EURneffy: A new era in needle-free emergency allergy treatment
The European Commission has approved ARS Pharmaceuticals’ adrenaline nasal spray for the emergency treatment of severe allergies, EURneffy.
Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain
Neurocrine Biosciences has achieved late-stage success with muscarinic M4 selective agonist in schizophrenia.
Nasal powder shows promise in boosting immune defense
The INNA-051 formulation is designed to enhance the body’s natural immune response, targeting individuals aged 60 and over who are at increased risk for complications from respiratory viral infections.
ALZpath and Beckman Coulter partner for breakthrough diagnostic
In the ongoing battle against Alzheimer’s disease, early diagnosis is crucial.
Astellas begins phase 3 trial of fezolinetant for VMS in breast cancer
Astellas Pharma Inc. has announced the initiation of its phase 3 pivotal study, Highlight 1, for fezolinetant, an investigational nonhormonal oral treatment for vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy.
EC Approves Balversa for patients with metastatic urothelial carcinoma
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has approved Balversa (erdafitinib) as a once-daily oral monotherapy for adult patients with unresectable or metastatic urothelial carcinoma (mUC)...
H1 Connect links doctors to global humanitarian missions
H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare networks to provide humanitarian aid in regions that need it most.
Breaking barriers in science: Thermo Fisher's Melanie Adams-Cioaba on innovation and inclusion
In the rapidly evolving field of drug discovery, Melanie Adams-Cioaba stands at the forefront, leading transformative advancements in cryo-electron microscopy (cryo-EM) at Thermo Fisher Scientific.
First severe plaque psoriasis oral therapy for ages 6-17 available in the US
Amgen has announced the US availability of Otezla (apremilast) for pediatric patients aged 6 to 17 with moderate to severe plaque psoriasis.
Gilead's Livdelzi granted accelerated FDA approval for primary biliary cholangitis
Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare and chronic autoimmune disease affecting the bile...
Ayvakit's explosive 185% revenue growth: A game-changer in rare disease treatment
Ayvakit, a groundbreaking therapy developed by Blueprint Medicines, has witnessed a remarkable 185% year-over-year revenue growth in the second quarter of this year (2024).
Lonza boosts clinical services with new bottling capabilities
Lonza, a global leader in the pharmaceutical, biotech, and nutraceutical markets, has announced a significant expansion of its clinical manufacturing services at its small molecules site in Bend, Oregon.
Tonix's trial results showing promise in fibromyalgia treatment
Tonix Pharmaceuticals has announced promising phase 3 trial results for TNX-102 SL (sublingual cyclobenzaprine HCl), a treatment targeting fibromyalgia.
Intelliguard and Cencora partner to streamline RFID medication management
Intelliguard, a leader in medication management and data-intelligence solutions, has announced a partnership with Cencora, a global pharmaceutical solutions provider.
Boosting pharma security: Systech's track and trace tech
In the fight against counterfeit pharmaceuticals, Systech stands at the forefront with its advanced track and trace technology.
How nuVizz transforms pharma supply chains: Insights from its CEO, Guru Rao
In the ever-evolving world of pharmaceutical logistics, nuVizz has emerged as a key player, delivering innovative solutions that streamline the delivery management process.
SSNL - track and trace
TraceLink and Tecsys partnership: healthcare supply chain with integrated digital solutions
In a strategic move aimed at transforming healthcare supply chains, TraceLink, a leading provider of digital supply chain solutions, has partnered with Tecsys, an industry leader in inventory and warehouse management systems.
Certa’s CEO Jag Lamba on enhancing pharma supply chain traceability and compliance
In an increasingly complex regulatory landscape, pharmaceutical companies face significant challenges in maintaining transparency and accountability across their global supply chains.
Improving clinical supply chains: An in-depth conversation with IQVIA's Stefan Duerr
In the intricate world of clinical trials, the integrity and efficiency of the drug supply chain are paramount.
FDA approval of needle-free spray, a major breakthrough in anaphylaxis treatment
Patients suffering from severe allergic reactions now have access to a new, needle-free treatment option, as the US Food and Drug Administration (FDA) has approved neffy, a 2 mg epinephrine nasal spray developed by ARS Pharmaceuticals, Inc.
Lykos’ heartache over FDA setback as new trial for groundbreaking PTSD treatment ordered
In a blow to millions of Americans battling post-traumatic stress disorder (PTSD), Lykos Therapeutics announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its new drug application (NDA) for...
DIA 2024
Using technology to transform clinical trials: An interview with PhaseV CEO Raviv Pryluk
In a rapidly evolving landscape where speed and precision are critical, the integration of advanced technologies in clinical trials is essential.
Bruker acquires stake in NovAliX, an alliance to revolutionize drug discovery
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
FDA to decide on Lykos' MDMA therapy for PTSD, offering hope for millions
The FDA is expected to make a pivotal decision on Sunday (August 11) regarding the approval of Lykos Therapeutics’ MDMA-assisted therapy for PTSD.